Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI Guided Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
NCT05108428Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in rectal adenocarcinoma, sponsored by Moffitt Cancer Center. Primary endpoint: Feasibility of MRI guided dose adaptive chemoradiation therapy at 6 weeks. Started Dec 2021; status: active, not recruiting.
02
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT05108428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108428.